Breaking News Instant updates and real-time market news.

CNDT

Conduent

$13.62

0.01 (0.07%)

, CTXS

Citrix

$106.16

1.15 (1.10%)

04:55
02/15/19
02/15
04:55
02/15/19
04:55

Healthcare Info & Management Systems Society to hold a conference

HIMSS19 Global Conference & Exhibition will be held in Orlando on February 11-15.

CNDT

Conduent

$13.62

0.01 (0.07%)

CTXS

Citrix

$106.16

1.15 (1.10%)

EPAY

Bottomline Technologies

$47.10

0.06 (0.13%)

EXTR

Extreme Networks

$7.69

0.185 (2.47%)

JCOM

j2 Global

$83.44

1.65 (2.02%)

LDOS

Leidos

$62.35

0.1 (0.16%)

PEGA

Pegasystems

$57.21

0.31 (0.54%)

PHG

Philips

$39.22

0.14 (0.36%)

PSTG

Pure Storage

$19.02

-0.02 (-0.11%)

SPOK

Spok

$14.13

0.08 (0.57%)

STRM

Streamline Health

$1.15

(0.00%)

VAR

Varian Medical

$131.71

-1.055 (-0.79%)

VCRA

Vocera

$30.33

-0.93 (-2.98%)

  • 19

    Feb

  • 20

    Feb

  • 20

    Feb

  • 22

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 13

    Mar

  • 20

    Mar

CNDT Conduent
$13.62

0.01 (0.07%)

08/14/18
JPMS
08/14/18
NO CHANGE
JPMS
JPMorgan upgrades Conduent, downgrades Cognizant and Genpact
JPMorgan analyst Tien-tsin Huang rebalanced his ratings in the IT/BPO Services sector while establishing 2019 price targets. Analyst Puneet Jain upgraded Conduent (CNDT) to Overweight from Neutral with a $24 price target. Jain is more confident that the company's turnaround can unlock earnings power based on first half of 2018 results. He recommends the stock along with DXC Technology (DXC) "among legacy IT services firms in transition." Huang downgraded Cognizant Technology Solutions to Neutral from Overweight saying there is "less margin for error at this point of its turnaround to expand margins and drive revenue growth." The analyst also downgrades Genpact (G) to Underweight from Neutral saying the company ranks at the bottom in terms of price target upside with only 9% upside. Further, the company faces the "burden of higher revenue growth expectations when a wait-and-see approach seems more prudent to us before assigning a higher target multiple," Huang tells investors in a research note.
08/14/18
JPMS
08/14/18
UPGRADE
Target $24
JPMS
Overweight
Conduent upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Tien-tsin Huang upgraded Conduent to Overweight with an unchanged price target of $24.
11/08/18
SBSH
11/08/18
NO CHANGE
Target $20
SBSH
Buy
Conduent earnings call 'terrible,' but selloff overdone, says Citi
Citi analyst Jim Suva says that while Conduent's earnings call was "terrible," the 29% pullback in the shares is overdone and offers a buying opportunity. He lowered his price target for the stock to $20 from $25 and maintains a Buy rating on the name. Conduent is trading below book value and "meaningfully" below one-times sales, Suva tells investors in a research note.
11/08/18
RHCO
11/08/18
NO CHANGE
Target $18
RHCO
Buy
Conduent price target lowered to $18 from $28 at SunTrust
SunTrust analyst Frank Atkins lowered his price target on Conduent to $18 after the company lowered its FY18 outlook along with its in-line Q3 earnings, but believes that the 29% decline in its stock price yesterday was overdone. The analyst keeps his Buy rating based on the company's continued progress in "driving margin improvement, focusing the business strategy and improving the balance sheet". Atkins lowers his FY19 EPS view to $1.09 from $1.31 but notes that he does not believe that Conduent's turnaround is "off-track".
CTXS Citrix
$106.16

1.15 (1.10%)

01/24/19
WEDB
01/24/19
NO CHANGE
Target $110
WEDB
Neutral
Citrix price target lowered to $110 from $115 at Wedbush
Wedbush analyst Daniel Ives lowered his price target for Citrix to $110 from $115 to reflect a bit more caution around the company's growth trajectory for 2019 and beyond. The analyst notes that the company delivered a "solid" Q4 and ended 2018 on a positive note after going through a complex restructuring and focus on moving to a cloud/subscription model over the past 18 months. That said, while the company maintained its guidance for 2019, it gave a softer than expected outlook for the March quarter with networking as the main culprit of weakness, he adds. Ives reiterates a Neutral rating on the shares.
01/24/19
JEFF
01/24/19
NO CHANGE
Target $85
JEFF
Underperform
Citrix 'significantly' overvalued on 'modest' growth, says Jefferies
Jefferies analyst John DiFucci says Citrix Systems results last night were "blamed on a transition to subscription, which has been going on for some time." The analyst continues to view Citrix as "well-run with near-optimized profitability and modest growth." He finds the stock "significantly" overvalued and keeps an Underperform rating on the shares with an $85 price target.
10/19/18
WEDB
10/19/18
INITIATION
Target $115
WEDB
Neutral
Citrix initiated with a Neutral at Wedbush
Wedbush analyst Daniel Ives initiated Citrix Systems with a Neutral rating and $115 price target, telling investors in a research note that he is confident in the company's ability to execute on margin expansion in 2019 and beyond, although this remains a "prove me" story on this front and will be a clear balancing act along with significant investments potentially needed to catalyze the cloud business.
10/25/18
JEFF
10/25/18
NO CHANGE
Target $85
JEFF
Underperform
Citrix shares remain overvalued after 'decent' Q3, says Jefferies
Jefferies analyst John DiFucci views Citrix Systems' Q3 results as "decent," saying it exceeded "modest expectations" driven by upside to Product & License. The analyst sees the company's valuation "as among the greatest dislocations in Software." He raised his price target for the shares to $85 from $83 and keeps an Underperform rating on Citrix.
EPAY Bottomline Technologies
$47.10

0.06 (0.13%)

02/01/19
RAJA
02/01/19
NO CHANGE
Target $65
RAJA
Strong Buy
Bottomline Technologies price target lowered to $65 from $77 at Raymond James
Raymond James analyst John Davis lowered his estimates for Bottomline Technologies and cut his price target on the stock to $65 from $77 stating that the company's Q2 results were in-line to slightly better "pretty much across the board" outside of subs and transactions. However, he believes there is likely "some ASC 606 related noise" and said "there certainly wasn't anything thesis-changing in the quarter." Davis keeps a Strong Buy rating on Bottomline shares.
02/01/19
CHLM
02/01/19
NO CHANGE
Target $55
CHLM
Hold
Bottomline Technologies price target cut to $55 from $63 at Craig-Hallum
Craig-Hallum analyst George Sutton maintained a Hold rating on Bottomline Technologies and cut his price target to $55 from $63, telling investors in a research note that while the company's headline results for Q2 were "reasonable," the details weren't particularly good with the important subs and transactions line missing estimates. Sutton believes the reduction in guidance to below the long-standing $300M revenue bogey for subscription and transaction revenue was disappointing, but was modestly encouraged that backlog improved a bit y/y vs. declines in the prior quarter.
02/01/19
DADA
02/01/19
NO CHANGE
Target $47
DADA
Neutral
Bottomline Technologies price target lowered to $47 from $56 at DA Davidson
DA Davidson analyst Peter Heckmann lowered his price target on Bottomline Technologies to $47 and kept his Neutral rating after its results, saying that Q2 revenues edged out his expectations but the guidance for Q3 was disappointing due to increased FX headwinds related to weaker GBP. The analyst adds that the "more significant decline in earnings guidance was not fully explained" on the call despite a number of questions on the matter, also lowering his FY20 and FY21 EPS forecasts by 18c and 20c respectively to $1.52 and $1.76.
02/04/19
BRRR
02/04/19
NO CHANGE
BRRR
Outperform
Bottomline target range lowered to $55-$60 from $60-$65 at Barrington
Barrington analyst Gary Prestopino lowered his price target range for Bottomline Technologies to $55-$60 from $60-$65 after the company reduced its fiscal 2019 guidance to reflect currency moves. The analyst slightly lowered his adjusted EBITDA estimates for fiscal 2019 and 2020 but keeps an Outperform rating on Bottomline.
EXTR Extreme Networks
$7.69

0.185 (2.47%)

08/09/18
DADA
08/09/18
NO CHANGE
Target $13
DADA
Buy
Extreme Networks price target lowered to $13 from $20 at DA Davidson
DA Davidson analyst Mark Kelleher lowered his price target on Extreme Networks to $13 after its in-line Q4 results and below-consensus outlook, saying the company appears to be struggling with the integration of its acquisitions for the 3rd consecutive quarter. Kelleher also keeps his Buy rating on Extreme Networks given its "solid networking business" and "competitive" Ethernet solutions in the wireless sector.
08/09/18
COWN
08/09/18
DOWNGRADE
COWN
Market Perform
Extreme Networks downgraded to Market Perform from Outperform at Cowen
01/14/19
DADA
01/14/19
NO CHANGE
Target $13
DADA
Buy
Extreme Networks 'compelling value play in networking', says DA Davidson
DA Davidson analyst Mark Kelleher kept his Buy rating and $13 price target on Extreme Networks, saying the company stands to outperform this year after its "acquisition strategy over the past two years set the foundation for solid revenue and earnings growth." The analyst notes that the company had struggled last year in integrating its Brocade asset acquisition, but believes that those issues have been resolved. Kelleher sees Extreme Networks as a compelling value play in the networking sector, anticipating steady growth across all of its product categories.
11/15/18
JMPS
11/15/18
NO CHANGE
JMPS
Market Perform
Cisco results bode well for Arista Networks, Nutanix, says JMP Securities
JMP Securities analyst Erik Suppiger noted that Cisco (CSCO) reported Q1 EPS and revenues ahead of consensus, stating that he believes the "robust" results bode well for the broader networing and security markets, including vendors such as Arista Networks (ANET), Nutanix (NTNX), Extreme Networks (EXTR) and Palo Alto Networks (PANW). Service provider bookings had positive growth for the second consecutive quarter, though management acknowledged that the growth may not be sustainable and Suppiger said he thinks this quarter included a large deal with T-Mobile (TMUS). The strength in data center and campus switching that Cisco called out suggests market demand trends are favorable for Arista and Extreme Networks, said the analyst. The strength in Cisco's hyperconverged infrastructure product, HyperFlex, suggests demand is favorable for Nutanix, he added. Suppiger, who views Cisco shares as fairly valued, keeps a Market Perform rating on the stock.
JCOM j2 Global
$83.44

1.65 (2.02%)

08/13/18
BARD
08/13/18
NO CHANGE
Target $92
BARD
Outperform
j2 Global weakness a buying opportunity, says Baird
Baird analyst William Power remains a buyer of j2 Global following its recent weakness. Power said while the display advertising market could continue to face challenges, he believes the growth areas within digital media, including its growing subscription business and accelerating fax trends, should help boost overall growth. Power reiterated his Outperform rating and lowered his price target to $92 from $95 on j2 Global shares.
10/18/18
WEDB
10/18/18
INITIATION
WEDB
Outperform
j2 Global initiated with an Outperform at Wedbush
12/20/18
WBLR
12/20/18
NO CHANGE
WBLR
Outperform
William Blair sees room for j2 Global to grow organically
After hosting investor meetings with management, William Blair analyst Jim Breen sees room for j2 Global to grow organically while admitting the majority of its growth will continue to come from acquisitions. The analyst views j2 as a "defensive stock with highly visible free cash flow and a stable dividend." He reiterates an Outperform rating on the shares.
10/19/18
WEDB
10/19/18
INITIATION
Target $95
WEDB
Outperform
j2 Global initiated with an Outperform at Wedbush
Wedbush analyst Daniel Ives initiated j2 Global with an Outperform rating and $95 price target, telling investors in a research note that he believes the company remains a "misunderstood story" by the Street as the company is still painted by many investors as a legacy fax player, serial M&A machine, and has low growth prospects/high margins that have largely played out over the past few years with headwinds ahead.
LDOS Leidos
$62.35

0.1 (0.16%)

01/03/19
01/03/19
NO CHANGE

Leidos granted patent for peptide class of checkpoint inhibitors
Leidos has been issued a U.S. patent covering methods for novel peptide-based PD-1 checkpoint inhibitors. The patent was fast-tracked under the USPTO's Patents 4 Patients program.
06/21/18
WELS
06/21/18
NO CHANGE
WELS
Leidos may have opportunity to regain lost TSA business, says Wells Fargo
After the Washington Business Journal reported that the Transportation Security Administration has terminated a $578M contract awarded to Peraton, Wells Fargo analyst Ed Caso noted that Leidos is the incumbent providing logistical support services for security screening equipment. If the contract goes back to rebid, Leidos' transition agreement will likely need to be extended further and the company may have an opportunity to recapture the "notable" loss, added Caso, who has an Outperform rating on Leidos shares.
01/04/19
WELS
01/04/19
NO CHANGE
Target $30
WELS
Outperform
Wells Fargo favors Perspecta, Booz Allen, CACI in government services
In a research note on government services companies, Wells Fargo analyst Ed Caso tells investors that he continues to favor Booz Allen Hamilton (BAH), CACI International (CACI), Leidos (LDOS), Perspecta (PRSP) and ManTech (MANT) as the government continues its shutdown, though he says near-term outperfomance may be difficult despite being "defensive" names. Caso notes that this shutdown is different than the 16-day shutdown in October 2013, as this time about 75% of the government is funded, particularly Defense/Intel versus none in 2013. Though services providers fell into the 2013 shutdown, then recovered starting mid-event, this time, investor concern has weighed on the group for a few months now, which he believes has dampened the group's traditional defensive characteristics.
12/21/18
COWN
12/21/18
NO CHANGE
Target $74
COWN
Outperform
Leidos downside limited given recent selloff, says Cowen
Cowen analyst Kai von Rumohr said he sees limited downside in Leidos since the stock is down roughly 18% since November. The analyst said improved bookings bode well for 2019 revenue growth and he believes Genesis activity will likely pick up in 2020. von Rumohr reiterated his Outperform rating and lowered his price target to $74 from $77 on Leidos shares.
PEGA Pegasystems
$57.21

0.31 (0.54%)

04/26/18
04/26/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Omega Healthcare (OHI) initiated with a Market Perform at Raymond James. 2. HighPoint Resources (HPR) initiated with an Overweight at JPMorgan. 3. Veritone (VERI) initiated with a Buy at DA Davidson. 4. Pegasystems (PEGA) initiated with a Buy at DA Davidson. 5. Apollo Medical (AMEH) initiated with a Buy at Dougherty. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/03/19
BNCH
01/03/19
NO CHANGE
BNCH
Activision, Canopy Growth among Best Ideas for first half of 2019 at Benchmark
Benchmark analysts selected their Best Ideas for the first half of 2019, naming 16 stocks, including: Activision Blizzard (ATVI), BioTelemetry (BEAT), Biofrontera (BFRA), Ctrip (CTRP), Huazhu Group (HTHT), II-VI (IIVI), Intevac (IVAC), LHC Group (LHCG), Meredith (MDP), Marvell (MRVL), NeoGenomics (NEO), Pegasystems (PEGA), Silicon Labs (SLAB), Varonis (VRNS), Canopy Growth (CGC) and Waitr Holdings (WTRH).
08/15/18
MUFG
08/15/18
NO CHANGE
Target $65
MUFG
Overweight
Pegasystems headline shortfalls due to higher subscription mix, MUFG says
MUFG analyst Stephen Bersey kept his Overweight rating and $65 price target on Pegasystems after its Q2 results, saying that despite the headline miss, the company had a solid quarter. The analyst states the reported shortfalls were due to a "higher subscription mix than either the company or the Street anticipated", adding that looking through the lens of annual contract value", the growth of 31% was "impressive". Bersey adds that Pegasystems is maintaining its operating momentum.
11/07/18
MUFG
11/07/18
NO CHANGE
Target $55
MUFG
Overweight
Pegasystems earnings miss due to 'elevated subscription mix', says MUFG
MUFG analyst Stephen Bersey kept his Overweight rating and $55 price target on Pegasystems after its Q3 results, saying the EPS miss was due to "an elevated subscription mix" which dampens near term revenues. The analyst believes that the company is still seeing a "healthy demand for its offerings" and has already started to "benefit from its revenue model transition".
PHG Philips
$39.22

0.14 (0.36%)

10/24/18
DBAB
10/24/18
NO CHANGE
DBAB
Philips named a Catalyst Buy at Deutsche Bank
Deutsche Bank named Philips as a Catalyst Buy, stating that it expects investors to look past the temporary slowdown in Personal Health and focus on the much stronger than expected performance of Philips' Diagnosis & Treatment division.
09/17/18
EXAN
09/17/18
UPGRADE
EXAN
Outperform
Philips upgraded to Outperform from Neutral at Exane BNP Paribas
09/13/18
BERN
09/13/18
INITIATION
BERN
Outperform
Philips initiated with an Outperform at Bernstein
Bernstein analyst Lisa Bedell Clive started Philips with an Outperform rating, saying the company is nearing completion of a long-term transition, as it has pivoted from its industrial roots to become a healthcare equipment and IT company. The analyst adds that in recent years, the R&D division has taken Philips' portfolio of medical equipment and home-based patient monitoring devices to the next level, with a focus on better inter-connectivity and the integration of data analytics, including the growing use of Artificial Intelligence.
10/02/18
FBCO
10/02/18
DOWNGRADE
FBCO
Neutral
Philips downgraded to Neutral from Outperform at Credit Suisse
PSTG Pure Storage
$19.02

-0.02 (-0.11%)

11/14/18
STFL
11/14/18
NO CHANGE
STFL
Checks point to continued momentum at NetApp, Pure Storage, says Stifel
Stifel analyst Matthew Sheerin said his checks with storage-focused value-added-resellers pointed to continued strong external storage sales momentum in the September quarter, adding that he is expecting relatively strong results for NetApp (NTAP) and Pure Storage (PSTG), which he believes are both market share gainers. Though positively biased on fundamentals for both stocks, he continues to favor NetApp, Sheerin tells investors. He maintains a Buy rating on NetApp and a Hold rating on Pure Storage.
11/20/18
PIPR
11/20/18
NO CHANGE
Target $25
PIPR
Overweight
Pure Storage price target lowered to $25 from $28 at Piper Jaffray
Piper Jaffray analyst Andrew Nowinski lowered his price target for Pure Storage to $25 on concerns that Street estimates for fiscal 2020 "could prove to be too aggressive." The analyst, however, views the company's Q3 results as "solid" and reiterates an Overweight rating on the shares. He attributes the 6% post-earnings share rally to the new cloud data services. These software services will run in Amazon Web Services and now enable the company to support a hybrid environment, Nowinski tells investors in a post-earnings research note. He calls this is a "game-changer" for Pure Storage, saying it makes the company more software-centric and provides "more valuation support."
02/11/19
PIPR
02/11/19
NO CHANGE
PIPR
Piper storage survey positive for Pure Storage, Nutanix, NetApp
Piper Jaffray conducted its fiscal Q4 Storage Reseller Survey by collecting feedback from 28 resellers and distributors. While only five of 14 vendors had net positive results versus six of the 14 last quarter, the firm saw "strong results" for Pure Storage (PSTG), Rubrik, Nutanix (NTNX), Veeam and NetApp (NTAP), analyst Andrew Nowinski told investors earlier in a research note. Pure Storage also had the strongest pipeline heading into the April quarter, added the analyst. The company's results sharply improved in the survey, with 67% of resellers citing "Above Plan" results, the highest level seen in three years, says Nowinski. The stock in early trading is up 19c to $18.47. Of those surveyed by Piper, 36% of resellers said they saw a negative impact from the U.S. government shutdown, with Dell (DELL), HP/3PAR (HPQ) and IBM (IMB) the most impacted.
12/11/18
WOLF
12/11/18
INITIATION
Target $25
WOLF
Outperform
Pure Storage initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Milunovich initiated Pure Storage with an Outperform rating and $25 price target, noting his view that "tech has a bias toward the new."
SPOK Spok
$14.13

0.08 (0.57%)

STRM Streamline Health
$1.15

(0.00%)

VAR Varian Medical
$131.71

-1.055 (-0.79%)

01/04/19
GSCO
01/04/19
UPGRADE
Target $129
GSCO
Buy
Varian Medical upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Isaac Ro upgraded Varian Medical Systems to Buy and raised his price target for the shares to $129 from $107. The company's guidance looks conservative given the new China quota, Ro tells investors in a research note. The new, larger quota in China has the ability to grant approximately 1,400 licenses by 2020, about a 50% increase on a per annum basis from the prior quota, says the analyst. He calls Varian an "out of consensus Buy idea" with China driving upside over the next two years.
01/24/19
JEFF
01/24/19
NO CHANGE
Target $145
JEFF
Buy
Varian Medical price target raised to $145 from $125 at Jefferies
Jefferies analyst Anthony Petrone raised his price target for Varian Medical to $145 saying the company posted a beat for fiscal Q1 despite an impact from tariffs. The analyst believes the company can sustain order growth in low-teens at least through fiscal 2020 and keeps a Buy rating on the shares.
11/27/18
UBSW
11/27/18
INITIATION
UBSW
Buy
Varian Medical initiated with a Buy at UBS
UBS analyst Matthew Taylor initiated Varian Medical with a Buy rating and $140 price target.
01/24/19
RBCM
01/24/19
NO CHANGE
Target $130
RBCM
Sector Perform
Varian Medical price target raised to $130 from $115 at RBC Capital
RBC Capital analyst Brandon Henry raised his price target on Varian Medical to $130 after its Q1 results, saying the company's "gross order outperformance" was geographically broad. The analyst also contends that the company is "benefiting from a strong new product portfolio and what appears to be a continued acceleration in radiation oncology market growth." Henry keeps his Sector Perform rating on the shares however, noting that the medium term trend in the worldwide radiation oncology market is "difficult to forecast."
VCRA Vocera
$30.33

-0.93 (-2.98%)

02/14/19
JEFF
02/14/19
NO CHANGE
JEFF
Vocera guidance relates more to device launch than competition, says Jefferies
After hosting meetings with a host of managements, Jefferies analyst Sean Dodge says Vocera Communications' (VCRA) "weak" revenue guidance "seems to relate more to the Smartbadge launch than to competitive intrusion." Further, interest in Teladoc's (TDOC) virtual-first offering continues to grow, with a Blues plan now seeking regulatory approval to launch an entirely new plan designed on the concept, Dodge tells investors in a research note. The analyst keeps Buy ratings on both Vocera and Teladoc.
02/11/19
CHDN
02/11/19
DOWNGRADE
CHDN
Neutral
Vocera downgraded to Neutral from Buy at Chardan
02/08/19
WBLR
02/08/19
NO CHANGE
WBLR
Outperform
Vocera earnings weakness a buying opportunity, says William Blair
William Blair analyst Ryan Daniels says he's a buyer of Vocera Communications on weakness today, "especially if shares trade into the lower-$30 range." The stock in premarket trading is 22% to $30.99. Despite the noise created by the new device launch, the analyst feels good about management's visibility toward achieving, or exceeding, its initial 2019 targets. Vocera's bookings performance and backlog sets it up well for 2019 and any uptick in device bookings should drive upside to numbers, Daniels tells investors in a post-earnings research note. He believes management's guidance could prove to be conservative since the company prefers to see how the new SmartBadge launch impacts sales performance before being more aggressive with 2019 expectations. Daniels keeps an Outperform rating on Vocera.
02/08/19
SBSH
02/08/19
DOWNGRADE
Target $33
SBSH
Neutral
Citi sees Vocera range-bound through 2019, downgrades to Neutral
Citi analyst Stephanie Demko downgraded Vocera Communications to Neutral from Buy and lowered her price target for the shares to $33 from $46. The analyst says the company's "weak" 4Q bookings and 2019 guidance overshot her "negative catalyst watch expectations." Although Vocera's fiscal 2019 revenue guidance of 4%-10% should prove conservative, setting the company up for beat/raise potential throughout the year, the company would have to post eight points of upside at the midpoint to come in line with prior buy-side expectations, Demko tells investors in a post-earnings research note. The analyst continues to like Vocera's clinical workflow strategy but she believes the shares could be range-bound through 2019.

TODAY'S FREE FLY STORIES

ETFC

E-Trade

$47.45

0.88 (1.89%)

17:33
02/17/19
02/17
17:33
02/17/19
17:33
Conference/Events
E-Trade to hold Education Day »

Education Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

PFE

Pfizer

$42.41

0.45 (1.07%)

12:56
02/17/19
02/17
12:56
02/17/19
12:56
Hot Stocks
Pfizer, EMD Serono announce publication of Phase 3 data for BAVENCIO plus INLYTA »

Merck KGaA, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 18

    May

MRK

Merck

$79.84

0.9 (1.14%)

, PFE

Pfizer

$42.41

0.45 (1.07%)

12:48
02/17/19
02/17
12:48
02/17/19
12:48
Hot Stocks
Merck presents results from Phase 3 KEYNOTE-426 study »

Merck (MRK) announced…

MRK

Merck

$79.84

0.9 (1.14%)

PFE

Pfizer

$42.41

0.45 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 11

    Apr

  • 18

    May

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

12:42
02/17/19
02/17
12:42
02/17/19
12:42
Hot Stocks
Aveo Pharmaceuticals presents TIVO-3 trial topline results »

Aveo Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARDM

Aradigm

$0.00

(0.00%)

12:34
02/17/19
02/17
12:34
02/17/19
12:34
Hot Stocks
Aradigm announces plans for reorganization under Chapter 11 »

Aradigm has filed for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

, XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

13:26
02/16/19
02/16
13:26
02/16/19
13:26
Periodicals
Amazon a risk for almost every stock/sector, Barron's says »

Amazon (AMZN) is eating…

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

KR

Kroger

$29.50

0.54 (1.86%)

FAST

Fastenal

$62.97

0.61 (0.98%)

GWW

Grainger

$316.63

4.9 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

YETI

Yeti

$22.85

0.97 (4.43%)

13:20
02/16/19
02/16
13:20
02/16/19
13:20
Periodicals
Yeti stock has 60% upside, Barron's says »

Yeti Holdings stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

L

Loews

$46.67

0.785 (1.71%)

13:14
02/16/19
02/16
13:14
02/16/19
13:14
Periodicals
Investors can love Loews, Barron's says »

Loews is a $15B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 28

    May

EQIX

Equinix

$421.53

1.16 (0.28%)

, COR

CoreSite Realty

$102.69

0.625 (0.61%)

13:10
02/16/19
02/16
13:10
02/16/19
13:10
Periodicals
Equinix, CoreSite Realty among stocks to play data-center boom, Barron's says »

Data-center stocks may…

EQIX

Equinix

$421.53

1.16 (0.28%)

COR

CoreSite Realty

$102.69

0.625 (0.61%)

IRM

Iron Mountain

$35.13

-0.14 (-0.40%)

INXN

Interxion

$64.65

0.81 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 26

    Mar

  • 26

    Mar

NOK

Nokia

$6.31

0.015 (0.24%)

, ERIC

Ericsson

$9.36

0.015 (0.16%)

13:07
02/16/19
02/16
13:07
02/16/19
13:07
Periodicals
A U.S. ban of Huawei may benefit Ericsson, Samsung, Barron's says »

The next salvo in the…

NOK

Nokia

$6.31

0.015 (0.24%)

ERIC

Ericsson

$9.36

0.015 (0.16%)

SSNLF

Samsung

$0.00

(0.00%)

CSCO

Cisco

$49.45

1.05 (2.17%)

JNPR

Juniper

$27.12

0.16 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

COP

ConocoPhillips

$70.13

1.04 (1.51%)

, MUR

Murphy Oil

$29.23

0.59 (2.06%)

13:00
02/16/19
02/16
13:00
02/16/19
13:00
Periodicals
Dividend investors should look to oil stocks for big yields, Barron's says »

Energy stocks aren't…

COP

ConocoPhillips

$70.13

1.04 (1.51%)

MUR

Murphy Oil

$29.23

0.59 (2.06%)

CVX

Chevron

$119.30

1.19 (1.01%)

VLO

Valero

$84.34

0.75 (0.90%)

XOM

Exxon Mobil

$77.74

1.47 (1.93%)

MRO

Marathon Oil

$17.07

0.15 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 07

    Mar

  • 18

    Mar

  • 22

    May

  • 28

    May

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

12:45
02/16/19
02/16
12:45
02/16/19
12:45
Periodicals
Protestors against NY's Amazon HQ2 got math wrong, Barron's says »

On Thursday, Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

, NDAQ

Nasdaq

$87.74

0.56 (0.64%)

12:28
02/16/19
02/16
12:28
02/16/19
12:28
Periodicals
Investors interested in U.S. cannabis companies face challenges, Barron's says »

Investors interested in…

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

NDAQ

Nasdaq

$87.74

0.56 (0.64%)

CGC

Canopy Growth

$47.54

1.49 (3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 28

    May

  • 15

    Feb

AMD

AMD

$23.68

0.55 (2.38%)

, INTC

Intel

$51.64

0.85 (1.67%)

08:43
02/16/19
02/16
08:43
02/16/19
08:43
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMD

AMD

$23.68

0.55 (2.38%)

INTC

Intel

$51.64

0.85 (1.67%)

MRVL

Marvell

$18.82

-0.37 (-1.93%)

MCHP

Microchip

$91.10

0.49 (0.54%)

MU

Micron

$41.99

-0.23 (-0.54%)

NVDA

Nvidia

$157.22

2.69 (1.74%)

QCOM

Qualcomm

$51.97

0.42 (0.81%)

TXN

Texas Instruments

$107.55

0.57 (0.53%)

TWTR

Twitter

$31.23

0.28 (0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 07

    Mar

  • 07

    Mar

  • 25

    Mar

  • 26

    Mar

  • 28

    May

  • 04

    Jun

  • 05

    Jun

AMGN

Amgen

$188.31

1.6 (0.86%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

04:55
02/16/19
02/16
04:55
02/16/19
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2019 ASCO Genitourinary…

AMGN

Amgen

$188.31

1.6 (0.86%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

AZN

AstraZeneca

$40.92

0.93 (2.33%)

BAYRY

Bayer

$0.00

(0.00%)

BMY

Bristol-Myers

$51.64

0.81 (1.59%)

CALA

Calithera Biosciences

$5.35

0.14 (2.69%)

CLVS

Clovis

$25.44

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

ESALY

Eisai

$0.00

(0.00%)

EXEL

Exelixis

$22.26

-0.05 (-0.22%)

IMMU

Immunomedics

$14.23

0.225 (1.61%)

INO

Inovio

$3.70

0.01 (0.27%)

MRK

Merck

$79.84

0.9 (1.14%)

MYOV

Myovant Sciences

$21.48

0.1 (0.47%)

MYGN

Myriad Genetics

$31.41

0.53 (1.72%)

NH

NantHealth

$0.60

(0.00%)

NVS

Novartis

$89.89

0.865 (0.97%)

PFE

Pfizer

$42.41

0.45 (1.07%)

PGNX

Progenics

$4.87

0.13 (2.74%)

SGEN

Seattle Genetics

$71.48

2.92 (4.26%)

SNY

Sanofi

$42.51

0.94 (2.26%)

TYME

Tyme Technologies

$3.19

0.055 (1.76%)

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 16

    Feb

  • 19

    Feb

  • 20

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

  • 11

    Mar

  • 22

    Mar

  • 11

    Apr

  • 28

    Apr

  • 18

    May

  • 20

    May

WES

Western Gas Partners

$49.52

0.38 (0.77%)

, WGP

Western Gas Equity

$32.38

0.2 (0.62%)

19:30
02/15/19
02/15
19:30
02/15/19
19:30
Recommendations
Western Gas Partners, Western Gas Equity analyst commentary at MUFG »

MUFG raises price targets…

WES

Western Gas Partners

$49.52

0.38 (0.77%)

WGP

Western Gas Equity

$32.38

0.2 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 15

    Feb

  • 04

    Mar

PXD

Pioneer Natural

$145.33

2.27 (1.59%)

19:19
02/15/19
02/15
19:19
02/15/19
19:19
Recommendations
Pioneer Natural analyst commentary at MUFG »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

ZTS

Zoetis

$95.38

2.16 (2.32%)

18:42
02/15/19
02/15
18:42
02/15/19
18:42
Hot Stocks
Zoetis CEO says: 'Diagnostics are more important in animals than humans' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$136.40

2.13 (1.59%)

18:22
02/15/19
02/15
18:22
02/15/19
18:22
Hot Stocks
Johnson & Johnson CEO: 'We ended 2018 with great results' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 25

    Feb

  • 25

    Feb

  • 06

    Mar

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

18:18
02/15/19
02/15
18:18
02/15/19
18:18
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

18:14
02/15/19
02/15
18:14
02/15/19
18:14
Hot Stocks
Biohaven treatment of multiple system atrophy granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$188.31

1.6 (0.86%)

18:11
02/15/19
02/15
18:11
02/15/19
18:11
Hot Stocks
Amgen treatment of Acute Myeloid Leukemia granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$100.19

1.19 (1.20%)

18:02
02/15/19
02/15
18:02
02/15/19
18:02
Hot Stocks
Celanese announces Acetyl Intermediates price increases in China »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

17:58
02/15/19
02/15
17:58
02/15/19
17:58
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

GLD

SPDR Gold Shares

$124.81

0.77 (0.62%)

17:41
02/15/19
02/15
17:41
02/15/19
17:41
Hot Stocks
SPDR Gold Shares holdings fall to 793.03MT from 796.85MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.